Q1 FY27 results analysis · August 12, 2026

Marksans Pharma Q1 FY27 Results Analysis: EBITDA Margin Expands 919 bps, Revenue Surges 35.6% YoY

+173.9%PAT year on year, Rs. 1,594.07 Cr
Cofacto ResearchPublished August 12, 20262 min readPositive read
Quick summary

Marksans Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 8,407.96 Cr (+35.61% YoY) and PAT growth of +173.89% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 12, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 8,407.96 Cr (+35.61% YoY)
PAT (Q1)Rs. 1,594.07 Cr (+173.89% YoY)
EBITDA margin25.34% (+919 bps YoY)
EPS (Q1)Rs. 3.47 (+168.99% YoY)
Market capRs. 14,168.44 Cr
CMPRs. 312.60

Quarter Snapshot

Marksans Pharma delivered 35.6% YoY revenue growth and a 919 bps EBITDA margin expansion to 25.34%, well above the FY27 guidance of 20-21%. The beat was driven by operating leverage and cost management, though standalone revenue was flat, and the consolidated growth relied heavily on subsidiaries.

Key Investment Insights

Key Positives

  • Revenue grew 35.6% YoY to Rs.8,407.96 Cr.
  • EBITDA margin expanded 919 bps YoY to 25.34%, above management's FY27 guidance of 20-21%.
  • PAT grew 173.9% YoY to Rs.1,594.07 Cr.
  • All major cost lines declined as a percentage of revenue YoY.
  • Standalone EBITDA margin improved to 25.56% from 21.91% a year ago.

Risk Factors

  • Standalone revenue was virtually flat YoY at +0.45%, indicating consolidated growth is primarily driven by subsidiaries.
  • Elevated other income (Rs.254.04 Cr) was not itemized; its sustainability is uncertain.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.